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ABSTRACT
Objectives: Estimate the efficacy of amoxicillin for acute
uncomplicated lower-respiratory-tract infection (LRTI) in
primary care and demonstrate the use of randomisation-
based efficacy estimators.
Design: Secondary analysis of a two-arm individually-
randomised placebo-controlled trial.
Setting: Primary care practices in 12 European
countries.
Participants: Patients aged 18 or older consulting with
an acute LRTI in whom pneumonia was not suspected by
the clinician.
Interventions: Amoxicillin (two 500 mg tablets three
times a day for 7 days) or matched placebo.
Main outcome measures: Clinician-rated symptom
severity between days 2–4; new/worsening symptoms
and presence of side effects at 4-weeks. Adherence was
captured using self-report and tablet counts.
Results: 2061 participants were randomised to the
amoxicillin or placebo group. On average, 88% of the
prescribed amoxicillin was taken. The original analysis
demonstrated small increases in both benefits and harms
from amoxicillin. Minor improvements in the benefits of
amoxicillin were observed when an adjustments for
adherence were made (mean difference in symptom
severity −0.08, 95% CI −0.17 to 0.01, OR for new/
worsening symptoms 0.81, 95% CI 0.66 to 0.98) as well
as minor increases in harms (OR for side effects 1.32,
95% CI 1.12 to 1.57).
Conclusions: Adherence to amoxicillin was high, and
the findings from the original analysis were robust to
non-adherence. Participants consulting to primary care
with an acute uncomplicated LRTI can on average expect
minor improvements in outcome from taking amoxicillin.
However, they are also at an increased risk of
experiencing side effects.
Trial registration numbers: Eudract-CT 2007-001586-
15 and ISRCTN52261229.
The trial was registered at EudraCT in 2007 due to an
administrative misunderstanding that EudraCT was a
suitable registry—which it was not in 2007, but has
become since. On discovery of this error, the trial was
also registered at ISRCTN ( January 2009). Trial
procedures did not change between the two registrations.
INTRODUCTION
Acute uncomplicated lower-respiratory-tract
infection (LRTI) is one of the most common
reasons for patients consulting in primary
care.1 2 Antibiotics are prescribed to the
majority of consulting patients, with amoxicil-
lin being the most common across Europe.3
Evidence for the beneﬁts and harms of anti-
biotic treatment has been unclear, primarily
Strengths and limitations of this study
▪ This is the largest randomised placebo-controlled
trial evaluating amoxicillin for acute, uncomplicated
lower-respiratory-tract infection in primary care to
date.
▪ Consideration of the benefits and harms of
amoxicillin allowed for a balanced assessment of
this treatment.
▪ Multiple types of adherence measures meant that
agreement between measures could be assessed.
▪ As is often the case in research, indirect measures
of medication adherence were collected. These rely
heavily on their inherent assumptions (eg, accurate
patient recall, returning of all unused medication).
Direct measures (eg, direct observation) are prefer-
able, but often not feasible in practice.
▪ Structural mean models enabled an adjustment
for treatment non-adherence while maintaining a
comparison of groups as randomised.
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due to underpowered and inappropriately designed
studies.4 With antibiotic resistance becoming a growing
problem worldwide, the need for clear evidence for the
beneﬁts and harms of antibiotics for this condition has
never been more of a priority.5 6
A recently published trial of amoxicillin for acute
uncomplicated LRTI in primary care concluded that
amoxicillin provides little clinical beneﬁt and causes slight
harms.7 The ﬁndings of this trial were based on a compari-
son of participants in the arm to which they were originally
randomised (ie, using the intention to treat (ITT) prin-
ciple). While an ITT analysis is an important part of the
analysis of any trial, as it reﬂects the design of the trial and
uses randomisation to avoid selection bias,8 this approach
does not take into account deviations that occur following
randomisation, such as lack of adherence to treatment.
Adherence to antibiotic treatment in primary care is
poor.9 Less than 60% of patients prescribed an antibiotic
for an acute cough/LRTI in primary care initiated their
treatment, and less than half took the full course.10 Poor
levels of adherence to antibiotics wastes healthcare
resources, could negatively impact on clinical outcomes
and could increase the selective pressures for antibiotic
resistance. When issues with adherence are present in a
trial, analysis based on the ITT principle underestimates
treatment effects, and can only provide an unbiased esti-
mate of the effect of prescribing treatment (effectiveness),
rather than the effect of treatment itself (efﬁcacy).11
Two traditional approaches to estimating treatment
efﬁcacy include per-protocol analysis, where participants
who do not adhere to their allocated treatment are
excluded from analyses, and on-treatment analysis,
where participants are analysed in the group corre-
sponding to the treatment they took (regardless of the
group they were allocated to).12 Both methods make the
implicit assumption that the groups of participants are
equivalent with respect to observed and unobserved vari-
ables, something that is implausible in practice.13
Approaches to estimating efﬁcacy without making this
key assumption exist, and are becoming increasingly
popular.14 15 However, these approaches are generally
reported in specialist methodological journals, rather
than the general medical literature and as such there
still remains a reliance on more traditional and arguably
inadequate methods.
The aim of this paper is to use the data set from the
largest placebo-controlled trial of amoxicillin for acute
uncomplicated LRTI in primary care to produce
adherence-adjusted estimates of the beneﬁts and harms
from amoxicillin for adults consulting in primary care
with an acute uncomplicated LRTI, while preserving a
comparison of groups as randomised.
METHODS
Study design and participants
A two-arm individually-randomised placebo-controlled
trial was conducted between November 2007 and
April 2010. Patients were recruited consecutively from
primary care practices from 12 European countries
(Belgium, England, France, Germany, Italy, the
Netherlands, Poland, Slovakia, Slovenia, Spain,
Sweden and Wales).
The trial has previously been described in detail else-
where.7 A brief description about recruitment, random-
isation, blinding, the interventions, data collection and
follow-up are given below. Further analyses were per-
formed in order to investigate our study question.
Recruitment, randomisation, blinding and interventions
Participants were eligible for inclusion if they were aged
18 years or older and consulting for the ﬁrst time with
either an acute cough (≤28 days’ duration) as their
main symptom, for which non-infective diagnoses were
judged very unlikely, or an illness in which cough was
not the most prominent symptom but the clinician
thought acute LRTI the most probable diagnosis.
Participants were deemed ineligible if their initial
diagnosis was community-acquired pneumonia (ie, com-
plicated LRTI) on the basis of focal chest signs (focal
crepitations, bronchial breathing) and systemic features
(high fever, vomiting, severe diarrhoea). Participants
were also ineligible if their working diagnosis was cough
of a non-infective cause (eg, pulmonary embolus, left
ventricular failure, oesophageal reﬂux, allergy), they
had used antibiotics in the previous month, were unable
to provide informed consent or complete the diary
(eg, they had dementia, psychosis or severe depression),
were pregnant, allergic to penicillin or had immuno-
logical deﬁciencies.
Participants were allocated to groups on a 1:1 basis
using block randomisation. As this was a double-blinded
trial, clinicians and participants were blinded to the ran-
domisation sequence and allocation. All outcome data
were also collected without prior knowledge of the
group to which participants were allocated.
Randomised participants received a prescription for
amoxicillin, to be taken as two 500 mg tablets three
times a day for 7 days, or a placebo identical in appear-
ance, taste and texture.
Data collection and participant follow-up
Consenting participants had their comorbidities, clinical
signs and symptoms recorded by the recruiting clinician.
Following recruitment, consent and randomisation,
participants were given a daily symptom diary to com-
plete for up to 28 days. The diary recorded the duration
and severity of 12 symptoms (cough, phlegm, shortness
of breath, wheeze, blocked or runny nose, chest pain,
muscle aches, headaches, disturbed sleep, general feeling
of being unwell, fever and interference with normal activ-
ities). Severity was scored on a scale from 0 to 6 (0=no
problem, 1=very little problem, 2=slight problem, 3=mod-
erately bad, 4=bad, 5=very bad, 6=as bad as it could be).
Patients also recorded non-respiratory symptoms, such as
diarrhoea, skin rash and vomiting.
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Members of the research team telephoned partici-
pants after 4 days to offer support and answer questions
about the completion of the diary. If the diary was not
returned after 4 weeks, brief information was collected
about symptom duration and severity. This information
was collected with either a short questionnaire or a stan-
dardised telephone call.
Measures of adherence
Using their daily symptom diary, participants recorded
whether or not they took their study medication on a
given day, and whether they took their study medication
according to the instructions. Where it was indicated
that participants did not take their study medication
according to the instructions, space was given to provide
more detail. Participants for whom a diary was not
returned were asked to state the number of days that
they took their study medication. This information was
collected using the short questionnaire/telephone call
described in the previous section. Participants were also
instructed to return their study medication bottles, com-
plete with any unused medication, at the end of the
trial. The number of tablets returned was recorded by
members of the research team.
Randomised participants were prescribed 42 tablets.
Adherence to study medication was deﬁned as the per-
centage of the correct number of tablets taken during
the ﬁrst 7 days of the follow-up period (ie, the period
for which the medication was prescribed). Three binary
deﬁnitions of adherence were also constructed in order
to provide sensitivity analyses around the continuous def-
inition. The three binary deﬁnitions were full (100%)
adherence versus not full adherence, at least the equiva-
lent of a 5-day course (approximately 71.4%) versus less
and at least one tablet versus no tablets.
Where participants indicated that they had taken
medication on a particular day, in the absence of infor-
mation to the contrary (eg, stating that they only took
one tablet three times a day instead of two tablets), the
assumption was made that a participant consumed all
study medication as instructed. Where medication
bottles were returned, it was assumed that the difference
between the number of tablets prescribed and the
number returned equated to the number of tablets con-
sumed. We also assumed that all tablets were consumed
during the ﬁrst 7 days of the follow-up period. Where a
short questionnaire or telephone call was conducted, it
was assumed that the correct numbers of tablets
were taken for the number of days medication was
reportedly taken.
Where multiple types of adherence measures were
available for a participant the agreement between mea-
sures, and the assumptions inherent in our deﬁnition of
adherence, were investigated.
Outcomes
To demonstrate the beneﬁts and harms of amoxicillin
in this population, and to illustrate the use of
randomisation-based efﬁcacy estimators, the paper con-
centrates on three of the outcomes described in the ori-
ginal paper. The ﬁrst was the mean clinician-rated
symptom severity between days 2 and 4 after initial pres-
entation. The second outcome was the development of
new or worsening symptoms, deﬁned as returning to the
clinician with new or worsening symptoms, new signs or
an illness requiring admission to hospital within the
4-week follow-up period. The third outcome was the
presence of any non-respiratory symptoms (diarrhoea,
skin rash or vomiting) during the 4-week follow-up
period. These speciﬁc symptoms were recorded as they
are known side effects of amoxicillin. The ﬁrst two out-
comes were used to demonstrate the clinical beneﬁts of
amoxicillin for patients with an acute uncomplicated
LRTI in primary care, with the third used to demon-
strate harms. The decision to exclude the outcome
“time to resolution of moderately bad symptoms” from
the analysis was made for two reasons. First, in order to
reduce the number of assumptions made when deriving
the deﬁnition of adherence (we have not made any
assumptions about adherence on individual days, but
would have to make this additional assumption to
perform analysis on this outcome). The second reason
was that standard techniques for adjusting time-to-event
outcomes for non-adherence rely on ﬁtting an acceler-
ated failure time model. The original outcome was ana-
lysed using a Cox proportional hazards model, and
therefore the outcome would initially require reanalys-
ing using an accelerated failure time model before an
adjustment could be made. As the results from this ana-
lysis cannot be directly compared with the ﬁndings from
the main paper, the decision to exclude this outcome
from consideration was made.
Statistical analysis
Participants and their adherence to study medication
were described using means (SDs), medians (IQRs) and
percentages as appropriate.
Participants for whom more than one measure of
adherence was available had their agreement between
measures compared using Bland and Altman limits of
agreement.16 Bland and Altman plots are presented with
jittering and semitransparency to highlight overlapping
data points. Where multiple types of adherence measures
were reported and there was disagreement between
values, the minimum value was used for analysis.
The between-group mean difference in symptom
severity on days 2 to 4 postrandomisation was estimated
using linear regression. The mean clinician-rated
symptom severity at baseline was controlled for as a cov-
ariate. The between-group odds of developing new or
worsening symptoms and of reporting any non-
respiratory symptoms in the 4 weeks following random-
isation were compared using logistic regression without
covariates. These analyses included participants on an
intention-to-treat basis. That is, they did not adjust for
deviations following randomisation. The analyses
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therefore provide an estimate of the effectiveness of
amoxicillin for patients with an acute uncomplicated
LRTI in primary care, and as an estimate of efﬁcacy, are
viewed as being biased towards the null.
To determine efﬁcacy in a way that preserves random-
isation (ie, provides a comparison of groups ie, inde-
pendent of observed and, importantly, unobserved
confounders), and is not biased towards the null, struc-
tural mean models (SMM) were used to compare the
between-group differences in the aforementioned out-
comes. By recognising that at the beginning of a trial, all
participants have two potential outcomes—one if they
are treated and one if they are not, a SMM relates a
treated participant’s observed outcome to their poten-
tially counterfactual outcome that would have been
observed had they received no treatment. Standard
approaches to ﬁtting a SMM rely on using observed
levels of exposure, and treating randomisation as an
instrument (ie, assuming that it is independent of both
observed and unobserved confounders and only effects
outcome through its effect on exposure). Estimation
procedures therefore rely on ﬁnding a value of the treat-
ment effect such that balance is achieved between
groups on the outcome (or potential outcome) in parti-
cipants who were not treated. The between-group mean
difference in symptom severity on days 2 to 4 was esti-
mated using a two-stage least squares instrumental vari-
ables regression model.17 To compare the odds of
developing new or worsening symptoms and reporting
any non-respiratory symptoms, a generalised linear
(double logistic) SMM was estimated via a generalised
method of moments procedure.18 The double logistic
SMM involved a two-step process whereby the association
between outcome (development of new or worsening
symptoms or reporting of side effects), trial arm and
adherence was modelled ﬁrst, with estimates from this
model used in the SMM in order to obtain correct SEs
(and hence correct 95% CIs). For more information on
the use of randomisation-based efﬁcacy estimators and
their core assumptions, including the Stata syntax used
to implement the SMMs, please see the online supple-
mentary appendices 1 and 2.
Results from the linear regression model are pre-
sented as adjusted mean differences with associated
95% CIs. Results from the logistic regression models are
presented as ORs with associated 95% CIs. For the SMM
(double logistic SMM), results are presented as both the
adjusted mean difference (OR) per % increase in adher-
ence and per 100% adherence, the latter of which can
be interpreted as the maximum possible efﬁcacy.
Additional analyses using the three binary deﬁnitions
of adherence were performed to investigate the sensitiv-
ity of the main efﬁcacy analyses to departures from the
assumed linear relationship between adherence and
outcome.
Data management and descriptive statistics were per-
formed using IBM SPSS Statistics V.20.19 All other ana-
lyses were performed using Stata V.13.20
RESULTS
Participants
In total, 2061 participants were recruited and rando-
mised to either the amoxicillin group (1038) or placebo
(1023; ﬁgure 1). The groups were well matched on base-
line characteristics (table 1).
Adherence to study medication
Adherence data were available for 1854 participants
(90% of all randomised participants). The majority of
participants had multiple types of measure recorded
(1214, or 58.9% of all randomised; ﬁgure 2).
Adherence to study medication was similar between
trial arms and relatively high overall. Average levels of
adherence were highest for responses obtained from
self-reported diaries and lowest for responses from self-
reported telephone. Adherence data were highly skewed
for all three measures and spanned the entire range of
possible responses (table 2).
Agreement between adherence measures
Where multiple types of adherence measures were avail-
able, self-reports (diary and telephone formats) provided
slightly higher estimates of adherence on average com-
pared to tablet counts (mean differences of 1.7 and 2.6
percentage points, respectively). The limits of agreement
when comparing diary and tablet count adherence
ranged from −26.8 (self-reported diary adherence was
calculated as 26.8 percentage points lower than tablet
count adherence) to 30.2 (self-reported diary adherence
was calculated as 30.2 percentage points higher than
tablet count adherence) and when comparing tele-
phone and tablet count from −21.8 to 26.9 (table 3).
Figure 3A, B provide an illustration of the level of agree-
ment between different types of measures. What is clear
from these ﬁgures is that adherence was high and was
generally good (most data points on both plots are clus-
tered around the coordinate (100, 0), indicating full
adherence and no difference between measures). For
the comparison of diary to tablet count adherence, 7%
of participants were outside the limits of agreement; for
the comparison of telephone to tablet count adherence,
5% of participants were outside the limits of agreement.
Taking the minimum reported adherence value
(where multiple values were reported), adherence to
study medication remained high and negatively skewed
(table 4 and ﬁgure 4).
Outcomes
Table 5 provides descriptive statistics for each of the
three clinical outcomes.
Effectiveness
Table 6 compares the effectiveness and efﬁcacy of
amoxicillin with respect to the various outcomes below.
As reported in the original paper, the adjusted
between-group mean difference in symptom severity
score on days 2 to 4 was slightly lower in the amoxicillin
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group than the placebo group (adjusted mean differ-
ence of −0.07, 95% CI −0.15 to 0.01).
Being allocated to the amoxicillin arm (ie, being pre-
scribed amoxicillin) was associated with decreased odds
of developing new or worsening symptoms in the 4 weeks
postrandomisation follow-up period. The odds of devel-
oping new or worsening symptoms were 21% lower for
participants who were prescribed amoxicillin than for
those prescribed a matched placebo (OR=0.79, 95% CI
0.63 to 0.99). When the effectiveness analyses were only
performed on participants for whom outcome and
adherence data were available, there was a 19% decrease
in the odds of developing new or worsening symptoms in
participants prescribed amoxicillin (OR=0.81, 95% CI
0.64 to 1.03).
Being prescribed amoxicillin was associated with a
28% increase in the odds of reporting non-respiratory
symptoms (side effects) in the 4 weeks postrandomisa-
tion (OR=1.28, 95% CI 1.03 to 1.59).
Efficacy
Adjusting for adherence using the SMM, a small
increase in the between-group mean difference in
symptom severity score for participants who complete
their course of amoxicillin was found (−0.08, 95% CI
−0.17 to 0.01).
Figure 1 CONSORT flow diagram.
Table 1 Baseline characteristics of trial participants
Baseline characteristic Amoxicillin Placebo
Women 624/1038 (60.1%) 600/1023 (58.7%)
Age (years) 48.6 (16.7) 49.3 (16.4)
Non-smoker (past or present) 477/1037 (46.0%) 483/1022 (47.3%)
Illness duration before index consultation (days) 9.5 (8.0) 9.3 (7.2)
Respiratory rate (breaths per minute) 16.9 (3.3) 16.9 (3.3)
Body temperature (°C) 36.7 (3.3) 36.8 (3.3)
Lung disease* 163/1037 (15.7%) 147/1023 (14.4%)
Mean severity score (all symptoms)† 2.1 (0.5) 2.1 (0.5)
Mean severity score (cough)† 3.1 (0.7) 3.2 (0.7)
Sputum production 814/1036 (78.6%) 824/1021 (80.7%)
Discoloured sputum‡ 481/968 (49.7%) 468/957 (48.9%)
Data are n/N (%) or mean (SD).
*Chronic obstructive pulmonary disease or asthma.
†Severity of symptoms: 1=no problem; 2=mild problem; 3=moderate problem; 4=severe problem.
‡Green, yellow or blood stained.
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Figure 5 provides an illustration of the effectiveness
and efﬁcacy of amoxicillin for the above outcome. The
treatment efﬁcacy when adherence is 0% is 0, the ITT
(effectiveness) is illustrated by the diamonds (positioned
at an adherence level of 88%—the patient-average), and
the maximum efﬁcacy when adherence is 100%.
The odds of developing new or worsening symptoms
remained lower in participants who took their full
course of amoxicillin (OR for 100% adherence to
amoxicillin=0.81, 95% CI 0.66 to 0.98).
A small increase in the odds of reporting non-respiratory
symptoms was found when adjusting for adherence (OR
for 100% adherence=1.32, 95% CI 1.12 to 1.57).
Sensitivity analyses
Reﬁtting the above efﬁcacy analyses with binary deﬁni-
tions of adherence, the results remained largely similar
and did not alter the conclusions drawn by either the
efﬁcacy or indeed the effectiveness analyses. The most
extreme deﬁnition of adherence (full vs not) yielded
the largest between group differences and the least
extreme (at least one tablet vs none) yielded the smal-
lest (table 7).
DISCUSSION
Principal findings
In this 12-country randomised placebo-controlled trial of
amoxicillin for acute uncomplicated LRTI in primary
care, reported levels of adherence to study medication
was very high. Prescribing amoxicillin in this setting was
shown to have modest improvements in symptom sever-
ity on days 2–4, and a decrease in the odds of develop-
ing new or worsening symptoms in the 4 weeks following
index consultation. However, this has to be balanced
with the odds of reporting non-respiratory symptoms
(side effects) in the 4 weeks following index consult-
ation, which also increased. Adjusting these ﬁndings for
Figure 2 Availability of different types of adherence data for
all 2061 randomised participants.
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adherence, the effect of taking amoxicillin in this setting
largely agreed with the effect of prescribing described
above. Given the high level of adherence reported in
the trial, the adjustments made were minor, though in
the expected direction. Compared to the effect of pre-
scribing amoxicillin (ie, including participants who may
take their medication to a varying degree), taking
amoxicillin was shown to further improve symptom
severity on days 2–4, further decrease the odds of devel-
oping new or worsening symptoms and further increase
the odds of reporting side effects.
Strengths and weaknesses
To date, this remains the largest randomised placebo-
controlled trial evaluating amoxicillin for acute, uncom-
plicated LRTI in primary care. By maintaining a broad
inclusion criteria, recruiting across a range of different
countries, and recruiting participants similar in nature
to previously conducted observational studies in this
setting,3 the ﬁndings of this study are likely to be widely
applicable.
This paper demonstrated that the ﬁndings of main
effectiveness analysis were robust to non-adherence to
treatment, and did so using a method of analysis that
was not prone to the usual selection biases that arise
when ITT ﬁndings are adjusted for treatment adherence
traditionally (eg, per-protocol analysis).
By considering the beneﬁts and harms, the study pro-
vided a comprehensive account of the consequences of
taking amoxicillin for an acute uncomplicated LRTI in
primary care.
Adherence to medication was assessed using self-report
and tablet count data, and while both only provided
indirect measures of medication adherence, relying
heavily on various assumptions (eg, accurate participant
recall, returning of all unused medication), both mea-
sures were often available for the same individual, allow-
ing for the assessment of agreement between measures.
Agreement was good, with adherence calculated as 100%
for both measures for the majority of participants.
The use of SMMs to adjust trial ﬁndings for non-
adherence was attractive as it allowed for a comparison
of groups that was independent of measured and
unmeasured confounders. However, for this comparison
to be valid, it relied on the key assumption that for parti-
cipants who were categorised as non-adherers, merely
being allocated to receive treatment had no effect on
outcome (the so-called exclusion restriction).21 While
this was likely to be a valid assumption for this study, as
participants and clinicians were blinded to allocation,
this is less likely to be valid for non-blinded studies.
Table 3 Difference between adherence measures and limits of agreement
Difference between
adherence measures
Self-reported diary adherence minus
tablet count adherence (n=1135)
Self-reported telephone adherence
minus tablet count adherence (n=80)
Mean 1.7 2.6
SD 14.5 12.4
Lower 95% limit of agreement −26.8 −21.8
Upper 95% limit of agreement 30.2 26.9
Figure 3 (A and B) Bland and Altman plots illustrating the
agreement between the self-reported (diary (A) and telephone
(B)) and tablet count adherence measures. Red solid line
represents perfect agreement between measures. Black solid
line represents the mean difference (bias) between measures.
Black dashed lines are the 95% limits of agreement. Where
data points took the same value (ie, when more than one
participant had both the same average and difference in
adherence), semitransparency and jittering effects were
applied to provide an illustration of the number of overlapping
data points. There were a large number of data points at (100,
0), and this is illustrated by the large cluster of jittered points
around this coordinate.
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Deﬁning adherence as a continuous measure made the
exclusion restriction more plausible, as the lowest level of
adherence could be deﬁned as receiving no treatment, a
level at which being allocated to either treatment group
should really have no effect on outcome. However, this
approach made the additional assumption that the effect
of receiving an increasing amount of treatment on
outcome increased linearly,22 which for a trial involving
medication is unlikely to be true. Sensitivity analyses were
conducted using various binary deﬁnitions of adherence,
ranging from one or more tablets (vs no tablets) to full
course (vs less than full course). While the former
increased the plausibility of the exclusion restriction, the
estimated treatment efﬁcacy was too conservative. The
latter analysis combined participants who would have
taken 99% of their medication with participants who
would have taken no medication and considered them all
as not adhering (and therefore assumed they would have
received no beneﬁt from being allocated to the amoxicil-
lin arm). This clearly violated the exclusion restriction.
However, the ﬁndings from the sensitivity analyses largely
agreed with the main ﬁndings (where adherence was
measured continuously), adding further strength to the
conclusions of the paper.
Despite the fact that incomplete outcome and adher-
ence data were minimal, their impact on ﬁndings
remains unknown. However, as the condition under
investigation is generally self-limiting, and outcome data
included worsening of illness (a composite outcome col-
lected from medical notes that included hospitalisation),
we do not believe that the small amount of missing data
would have severely impacted on the ﬁndings or conclu-
sions drawn from this study. Indeed, sensitivity analyses
demonstrate that clinical conclusions remain largely
unaltered even when taking an extreme assumption
about missing adherence data (see online supplemen-
tary appendix 3 for further details).
Comparison to existing literature
The ﬁndings from this study concur with those reported
in the main ﬁndings paper,7 both of which are consist-
ent with a recently published Cochrane review of anti-
biotics for acute bronchitis.3
Adherence to amoxicillin in this study was consider-
ably higher than that reported in an observational study
of antibiotics for adults with acute cough/LRTI in
primary care.10 However, the participants recruited into
this trial were similar to those recruited into the afore-
mentioned observational study in terms of their baseline
characteristics.3
Approaches for adjusting treatment effects for non-
adherence while preserving randomisation have been in
existence for approximately 20 years.21 However, they
have largely been consigned to specialist methodological
journals, rarely used in practice and when used, gener-
ally focussed on non-pharmacological treatments.23
A recent publication using the same SMM approach as
this paper on a clinical trial involving patients with
depression demonstrates further that these methods are
becoming more mainstream and should be reported
alongside standard ITT estimates of treatment effective-
ness, when there is also interest in knowing the efﬁcacy
of treatment.24
Implications
The slight beneﬁts gained from taking amoxicillin in
adults consulting to primary care with acute uncompli-
cated LRTI must be balanced against the slight harms
that amoxicillin causes in terms of side effects, as well as
the associated contribution to antibiotic resistance.
While estimating the effectiveness of treatment using
the ITT principle remains the gold standard in clinical
trials, an ITT analysis only tells us the population-average
effect that prescribing treatment has. The analysis there-
fore provides the answer to a question that is of primary
interest to clinicians and policymakers (“What are the
effects when this drug is prescribed?”). However, to a
patient, the analysis may not be as informative (“What are
the effects when I take this drug as prescribed?”). Some
of these prescriptions will not be taken in their entirety,
others not at all. In general, an ITT analysis does not esti-
mate how good the medication is at treating the illness
Table 4 Levels of adherence to study medication used for statistical analyses (with the minimum value reported when
participants had more than one type of measure)
Amoxicillin (n=930) Placebo (n=924) Overall (n=1854)
Mean (SD) 88.0 (25.8) 86.6 (27.2) 87.3 (26.5)
Median (IQR) 100.0 (95.2–100.0) 100.0 (85.7–100) 100.0 (90.5–100.0)
Minimum–maximum 0.0–100.0 0.0–100.0 0.0–100.0
Figure 4 Proportion of participants at each adherence level
(with the minimum value reported when participants had more
than one type of measure).
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Table 6 Comparison of effectiveness and efficacy of amoxicillin for acute uncomplicated LRTI in primary care
Outcome Effectiveness*
Effectiveness for
whom adherence data
were also available†
Efficacy per 10%
increase in adherence†
Maximum efficacy
(100% adherence)†
Adjusted between-
group mean difference
in symptom severity
between days 2 and 4
postrandomisation
−0.07 (−0.15 to 0.01) −0.07 (−0.15 to 0.01) −0.008 (−0.017 to 0.001) −0.08 (−0.17 to 0.01)
OR for developing new
or worsening symptoms
in the 4 weeks
postrandomisation
0.79 (0.63 to 0.99) 0.81 (0.64 to 1.03) 0.978 (0.960 to 0.998) 0.81 (0.66 to 0.98)
OR for reporting
non-respiratory
symptoms/side effects
in the 4 weeks
postrandomisation
1.28 (1.03 to 1.59) 1.28 (1.04 to 1.59) 1.028 (1.011 to 1.046) 1.32 (1.12 to 1.57)
*Analysis based on 1789, 2027 and 1727 participants for the symptom severity, new symptoms and side effect outcomes, respectively.
†Analysis based on 1787, 1923 and 1725 participants for the symptom severity, new symptoms and side effect outcomes, respectively.
LRTI, lower-respiratory-tract infection.
Table 5 Descriptive statistics of the three outcome measures
Outcome Amoxicillin Placebo
Mean symptom severity between days 2 and 4 postrandomisation* 1.6 (0.8) 1.7 (0.8)
Development of new or worsening symptoms in the 4 weeks postrandomisation 162/1021 (15.9) 194/1006 (19.3)
Reported non-respiratory symptoms/side effects in the 4 weeks postrandomisation 249/867 (28.7) 206/860 (24.0)
Data are n/N (%) or mean (SD).
*Each symptom was scored from 0–6 (0=no problem, 1=very little problem, 2=slight problem, 3=moderately bad, 4=bad, 5=very bad, 6=as
bad as it could be).
Figure 5 Graphical illustration of the effectiveness and efficacy of amoxicillin on mean symptom severity on days 2–4.
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under consideration. Adjusting for adherence does allow
for the estimation of this. If an ITT analysis shows little
evidence of beneﬁt, but an adherence-adjusted analysis
demonstrates beneﬁt, then the attention of policymakers
should turn to ensuring that patients take their treatment
properly. Estimating efﬁcacy can provide additional
insight into the potential beneﬁt from treatment, and
can indicate whether additional resources need to be
allocated to the improvement of adherence to medica-
tion for speciﬁc conditions.
As was seen in this paper, if an ITT analysis ﬁnds little
evidence of any beneﬁt, and these conclusions are not
affected by an adherence-adjusted analysis, it can be con-
cluded that the intervention does not work in practice or
principle.
Estimating efﬁcacy in clinical trials while preserving the
random allocation of participants to treatment groups is
vital for inferring causal treatment effects. Standard soft-
ware is available for implementing methods such as the
SMM, and should become more widely used and
reported in the medical literature.
Future research
While the main ﬁndings paper reported that a subgroup
of older participants (aged 60 years or older) received
no differential effect of treatment, investigating the efﬁ-
cacy of amoxicillin in this subgroup may be beneﬁcial.
The SMM as presented in this paper relies on the
assumption of a linear relationship between adherence
(dose) and treatment efﬁcacy. The incorporation of
non-linear dose–response relationships into SMMs may
increase the applicability of these methods in clinical
trials, and is something that needs further attention.
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